Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Neoplasms 3Lymphoma 3Preleukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Esophageal Neoplasms 2Bone Marrow Diseases 2Sarcoma 1Primary Myelofibrosis 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms, Plasma Cell 1

Interventions

Carboplatin 6pembrolizumab 3Paclitaxel 3Observation 3Capecitabine 3Azacitidine 3venetoclax 2pertuzumab 2olaparib 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Oxaliplatin 2Irinotecan 2Immunotherapy 2Chemoradiotherapy 2130-nm albumin-bound paclitaxel 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tegafur-gimeracil-oteracil 1taxane 1talazoparib 1tagraxofusp 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Patient Reported Outcome Measures × 1 year × Clear all
NCT05926024 2026-03-11

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

UNC Lineberger Comprehensive Cancer Center

Active not recruiting
253 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡